• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Asunaprevir     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatProteaseInhibitors, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingpersondul:ChemicalObjectchemical substanceChemical compoundyago:WikicatCyclopropanesyago:WikicatMolecularFormulasyago:WikicatSulfonamidesyago:Abstraction100002137yago:Agent114778436yago:Anesthetic102710766yago:Antibacterial102716205yago:Antiviral102725367yago:CausalAgent100007347yago:Communication100033020yago:Cyclopropane103155661yago:Drug103247620yago:Formula106816935yago:GeneralAnesthetic103433434yago:InhalationAnesthetic103570838yago:Matter100020827yago:Medicine103740161yago:Message106598915yago:MolecularFormula106817173yago:PhysicalEntity100001930yago:ProteaseInhibitor104013993chemical compoundyago:Statement106722453yago:Substance100020090yago:SulfaDrug104352070yago:WikicatProteaseInhibitors New Facet based on Instances of this Class

Asunaprevir (formerly BMS-650032, brand name in Japan and Russia Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013. Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3. Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.